Comparison of phoenix and VITEK 2 extended-spectrum-β-lactamase detection tests for analysis of Escherichia coli and Klebsiella isolates with well-characterized β-lactamases

被引:37
作者
Thomson, Kenneth S. [1 ]
Cornish, Nancy E.
Hong, Seong G.
Hemrick, Kim
Herdt, Christian
Moland, Ellen S.
机构
[1] Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Ctr Res Antiinfect & Biotech, Omaha, NE 68178 USA
[2] Methodist Hosp, Microbiol Lab, Omaha, NE 68114 USA
关键词
D O I
10.1128/JCM.00776-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The VITEK 2 and Phoenix extended-spectrum beta-lactamase (ESBL) detection systems, which comprise confirmatory tests and expert systems, were evaluated for their ability to discriminate between 102 well-characterized strains of ESBL-positive or -negative Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca. At least 38 distinct ESBLs were included. The strains were chosen to include some known to cause false-positive and false-negative CLSI ESBL confirmatory test results. Therefore, enzyme characterizations, rather than CLSI tests, were the reference methods for the Phoenix and VITEK 2 evaluations. A third arm of the study was conducted with the Phoenix test using two normally inactive expert rules intended to enhance ESBL detection, in addition to using the currently available software. The Phoenix ESBL confirmatory test and unmodified expert system exhibited 96% sensitivity and 81% specificity for ESBL detection. Activation of the two additional rules increased sensitivity to 99% but reduced the specificity to 58%. The VITEK 2 ESBL confirmatory test exhibited 91% sensitivity, which was reduced to 89% sensitivity by its expert system, while its specificity was 85%. Many of the expert system interpretations of both instruments were helpful, but some were suboptimal. The VITEK 2 expert system was potentially more frustrating because it provided more inconclusive interpretations of the results. Considering the high degree of diagnostic difficulty posed by the strains, both ESBL confirmatory tests were highly sensitive. The expert systems of both instruments require modification to update and enhance their utility.
引用
收藏
页码:2380 / 2384
页数:5
相关论文
共 18 条
[1]  
[Anonymous], [No title captured]
[2]   Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City [J].
Bradford, PA ;
Bratu, S ;
Urban, C ;
Visalli, M ;
Mariano, N ;
Landman, D ;
Rahal, JJ ;
Brooks, S ;
Cebular, S ;
Quale, J .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (01) :55-60
[3]   Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York [J].
Bratu, S ;
Landman, D ;
Alam, M ;
Tolentino, E ;
Quale, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :776-778
[4]   Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York:: Epidemiology and recommendations for detection [J].
Bratu, S ;
Mooty, M ;
Nichani, S ;
Landman, D ;
Gullans, C ;
Pettinato, B ;
Karumudi, U ;
Tolaney, P ;
Quale, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) :3018-3020
[5]   MORE EXTENDED-SPECTRUM BETA-LACTAMASES [J].
JACOBY, GA ;
MEDEIROS, AA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (09) :1697-1704
[6]   Evaluation of the Etest ESBL and the BD Phoenix, VITEK 1, and VITEK 2 automated instruments for detection of extended-spectrum beta-lactamases in multiresistant Escherichia coli and Klebsiella spp. [J].
Leverstein-van Hall, MA ;
Fluit, AC ;
Paauw, A ;
Box, ATA ;
Brisse, S ;
Verhoef, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) :3703-3711
[7]   Prevalence of newer β-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002 [J].
Moland, Ellen S. ;
Hanson, Nancy D. ;
Black, Jennifer A. ;
Hossain, Ashfaque ;
Song, Wonkeun ;
Thomson, Kenneth S. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (09) :3318-3324
[8]   Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates [J].
Moland, ES ;
Hanson, ND ;
Herrera, VL ;
Black, JA ;
Lockhart, TJ ;
Hossain, A ;
Johnson, JA ;
Goering, RV ;
Thomson, KS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (03) :711-714
[9]   Extended-spectrum β-lactamases:: a clinical update [J].
Paterson, DL ;
Bonomo, RA .
CLINICAL MICROBIOLOGY REVIEWS, 2005, 18 (04) :657-+
[10]  
Poirel L., 2002, Current Pharmaceutical Biotechnology, V3, P117, DOI 10.2174/1389201023378427